Par Pharmaceutical Names Terrance J. Coughlin Chief Operating Officer
Woodcliff Lake, NJ, April 1, 2014 – Par Pharmaceutical Companies, Inc. today announced that Terrance J. Coughlin has been named chief operating officer. In this capacity, Mr. Coughlin will be responsible for Par's global manufacturing activities, research and development efforts and will be instrumental in the new product selection process.
Mr. Coughlin joins Par from Glenmark Generics, Inc. USA/Glenmark Generics Limited where he most recently served as president and chief executive officer for more than six years. Prior to that position, he served as president, Glenmark Generics Inc., USA. During his tenure with Glenmark, which began in 2004, Mr. Coughlin had overall responsibility for the North American, Western European and Eastern European generics businesses, as well as the global active pharmaceutical ingredient (API) business and Glenmark's generics operations in India. Prior to Glenmark, he served as senior vice president at Dr. Reddy's Laboratories, Inc., which he joined in 1995. At Reddy's, Mr. Coughlin progressed through a series of positions of increasing responsibility until he was eventually responsible for North American, European and global key account bulk active ingredient operations.
"Having worked with Terry, I know personally that he is a talented and capable senior manager with a proven track record of success," said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies. "Terry's more than 25 years' experience in the pharmaceutical industry extends from API to finished dosage, and from R&D to sales and marketing. He has managed businesses, including manufacturing facilities, in the U.S. and abroad. Terry's breadth of experience will serve Par well and I am excited to welcome him to our company."
Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company, Inc., working in quality control and assurance before advancing into marketing and sales management. He earned a B.S. in chemistry from Central Michigan University in 1988.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.
Par Pharmaceutical Companies, Inc.